October 2026 update: Elevance Health announced that it will release third-quarter results before the market opens on October 21, with a management call later that morning. As of October 7, Q3 numbers are not available, making the upcoming report the next important test for ELV shares. The latest reported quarter showed higher adjusted earnings guidance, but also a rising benefit expense ratio and declining membership. For a new investor, the useful question is whether profit growth is supported by durable insurance operations, not just whether the latest earnings figure looks strong.
Elevance Health Inc. (NYSE: ELV) sells health insurance plans and provides pharmacy, care-management, and related services. Its stock can respond quickly to medical costs, enrollment changes, government program rates, and guidance. This guide defines the measures to watch, explains what the latest company data does and does not show, and gives a practical routine for checking whether the share-price trend is supported by operating results.
What changed most recently, and what is still unknown?
On October 5, Elevance confirmed that it will publish Q3 2026 results at 6:00 a.m. Eastern Time on October 21 and review them with investors at 8:30 a.m. ET. This is a scheduled reporting event, not a result or guidance change. The report should help investors test whether pricing and cost management are keeping pace with medical claims and whether membership trends are developing as management expected.
For a dated price reference, the market snapshot available for this review showed ELV at $400.12 at 2:50 p.m. Eastern Time on October 6, up $5.61, or about 1.42%, from the previous close. This was an intraday quote, not the final October 6 closing price. A single session cannot confirm a price trend. Readers should refresh the company’s stock quote and chart before making any decision and use several weeks or months of price history for trend analysis.
Start with how a health insurer earns money
Elevance’s Health Benefits business collects premiums and pays members’ covered medical claims. Carelon includes pharmacy and care-service businesses that provide additional revenue and services. Because the company combines insurance and service operations, total revenue alone does not describe profitability. A small increase in premiums can coincide with weaker operating gain if claims or expenses rise faster.
One central measure is the benefit expense ratio, sometimes called a medical loss ratio by investors. It represents benefit expenses as a percentage of premium revenue. If the ratio rises, a larger share of each premium dollar is going to covered medical care, leaving less to pay administrative costs and support operating income, all else equal. The ratio can also shift with customer mix, claim timing, premium rates, and seasonal patterns, so a single quarter is a clue rather than a verdict.
Elevance reported a Q2 2026 benefit expense ratio of 89.7%, up 0.8 percentage points from a year earlier. A basis point is one-hundredth of a percentage point, so 80 basis points equal 0.8 percentage points. The company attributed the increase mainly to elevated medical-cost trends in government businesses, partly offset by improved results in Individual ACA plans. This is a key item to revisit in the Q3 report.
What did Q2 2026 show about earnings quality?
Elevance reported $49.8 billion of operating revenue for Q2, up 0.8% year over year. Diluted earnings per share, or EPS, were $6.71; adjusted diluted EPS was $7.45. EPS divides a company’s earnings available to shareholders by its diluted share count. Adjusted EPS excludes specified items, so it can help compare operating periods, but it is not the GAAP result and should be reviewed alongside the reconciliation in the company’s release.
The Q2 release said results included an approximately $0.80-per-share net below-the-line benefit. “Below the line” generally refers to items recorded outside operating income, such as certain financing, investment, or tax effects. The exact components should be checked in the company’s reconciliation; do not automatically assume this benefit will recur or use the full reported EPS increase as a recurring run rate.
The company raised its full-year 2026 guidance to at least $27.00 in adjusted diluted EPS, at least $20.10 in GAAP diluted EPS, and at least $6.0 billion in operating cash flow. It also said it was investing in medical-cost management, member and provider experience, operating efficiency, and Carelon. These targets are management expectations, not guarantees. Q3 results should show whether the higher forecast remains supported by ongoing operations.
Why does membership matter if revenue is growing?
Medical membership was about 44.9 million at June 30, down 469,000 sequentially. Elevance described anticipated declines in Medicare Advantage, Medicaid, and employer risk-based membership, along with a known commercial fee-based customer transition. Premium increases and growth in CarelonRx revenue helped offset those changes in the revenue line.
Membership can be a leading indicator, but the headline count should be read by product. Losing lower-margin members may have a different financial effect from losing members in a profitable plan. Also check the mix of risk-based plans, where the insurer bears more direct medical-cost risk, and fee-based plans, where revenue is more tied to administration or services. Ask whether the remaining customers generate sustainable margins and whether expected attrition was already built into guidance.
A beginner’s routine for analyzing the ELV price trend
- Choose the chart period. A daily move can reflect short-term trading. A three- to twelve-month chart is more useful for a medium-term view. Compare the same dates for ELV and a relevant healthcare benchmark or peer group.
- Describe the direction before predicting it. Higher highs and higher lows can indicate an advancing pattern; lower highs and lower lows can indicate a declining pattern. Moving averages, such as the 50-day and 200-day, smooth daily noise, but they lag and are not buy or sell signals by themselves.
- Connect price moves to the business. After October 21, compare revenue, the benefit expense ratio, membership by product, operating expenses, cash flow, and guidance with Q2. A price rise supported by improving medical-cost performance and stable membership is more meaningful than one supported by a single adjusted EPS figure.
- Check capital returns in context. Elevance repurchased 0.7 million shares for $234 million and paid a $1.72-per-share dividend in Q2. Buybacks and dividends return cash to shareholders, but their sustainability depends on earnings, liquidity, and investment needs. Do not treat a dividend yield or repurchase authorization as proof that the stock is undervalued.
- Set a reassessment rule. Decide which evidence would make you revisit your view, such as a further increase in the benefit expense ratio, weaker operating cash flow, guidance reductions, or membership losses beyond what management expected.
Which signals matter most in the next report?
| Signal to review | Why it matters | What deserves a closer look |
|---|---|---|
| Benefit expense ratio | Shows medical costs relative to premium revenue | Another increase or a gap between pricing and claims trends |
| Membership by product | Shows the size and mix of the insured base | Medicare Advantage, Medicaid, or employer attrition beyond plans |
| Operating gain and margin | Shows whether revenue is converting into operating profit | Revenue growth accompanied by lower operating gain |
| Adjusted and GAAP EPS | Separates management’s comparable measure from reported earnings | A wider gap caused by items that are not part of core operations |
| Operating cash flow | Shows cash generated after operating needs and claims timing | Results affected by payment timing that do not repeat |
Common mistakes to avoid
- Reading adjusted EPS as the whole story. Review the reported figure and reconciliation, including the disclosed below-the-line benefit.
- Assuming higher premiums always mean higher profit. Medical claims, customer mix, and operating costs can absorb premium gains.
- Calling one rebound a confirmed recovery. Look for several weeks of price action and confirmation from new operating data.
- Comparing different time periods or definitions. Use matching quarters and understand how a company defines adjusted measures before comparing them with competitors.
- Treating guidance as a promise. Government program rules, utilization, provider costs, and customer enrollment can change the result.
How to judge whether the trend is holding up
As of October 7, the evidence is mixed. Elevance’s higher full-year adjusted EPS and cash-flow guidance support the earnings outlook, while low revenue growth, a higher benefit expense ratio, and lower membership make execution important. The October 21 report is the next practical checkpoint. A stronger quality trend would pair stable or improving medical-cost performance with sound operating cash flow and guidance delivery. If costs accelerate or enrollment weakens more than expected, reassess the assumptions behind any positive chart pattern.
There are limits to this method. Price charts summarize past trading and cannot show future medical claims. Quarterly ratios can be distorted by seasonality, reserves, and customer mix. Adjusted metrics help with comparisons but are not standardized across every company. Use Elevance’s Q2 earnings release, its Form 10-Q, and the Q3 earnings schedule as primary references.
Information cutoff: October 7, 2026. This article is for general information and is not individualized investment advice.